Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is devoted to developing and commercializing novel therapeutics that treat respiratory, central nervous system and other disorders. The company's primary programs consist of a partial dopamine agonist, SLS-006, for patients with Parkinson's disease, an intranasal racemic ketamine, SLS-002, that treats suicidal ideation in patients with major depressive disorder, and SLS-005, a protein stabilizer that targets Sanfilippo syndrome and amyotrophic lateral sclerosis. Expanding their reach beyond these prototypes, Seelos also works on preclinical programs including a peptidic inhibitor, SLS-007, for Parkinson's patients, pediatric indications via SLS-008, H3 receptor antagonist SLS-010 and SLS-012. This ground-breaking company was estabilished in 2016, and its headquarters is located in New York, New York.
Seelos Therapeutics, Inc.'s ticker is SEEL
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 1-10 employees working at Seelos Therapeutics, Inc.
It is https://seelostherapeutics.com/
Seelos Therapeutics, Inc. is in the Healthcare sector
Seelos Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Seelos Therapeutics, Inc.'s industry peers: